Management of restless legs syndrome augmentation

Current Treatment Options in Neurology

Volumn 11, Issue 5, 2009, Pages 327-332

  Williams, Anne Marie ^a   Garcia Borreguero, Diego ^a  

^a SLEEP RESEARCH INSTITUTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; LEVODOPA; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SEROTONIN UPTAKE INHIBITOR;

AKATHISIA; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; LEG DISEASE; LONG TERM CARE; LOW DRUG DOSE; REBOUND; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; RESTLESS LEGS SYNDROME AUGMENTATION; REVIEW; RISK REDUCTION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT DURATION;

EID: 68949147850     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-009-0036-2     Document Type: Review

References (33)

1. von Scheele C, Kempi V: Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990, 47: 1223-1224.
2. Silber MH, Girish M, Izurieta R: Pramipexole in the management of restless legs syndrome: An extended study. Sleep 2003, 26: 819-821.
3. Happe S, Trenkwalder C: Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 2004, 18: 27-36.
4. Allen RP, Earley CJ: Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19: 205-213.
5. Allen RP, Picchietti D, Hening WA, et al.: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4: 101-119.
6. Garcia-Borreguero D, Allen RP, Kohnen R, et al.: Diagnostic standards for dopaminergic augmentation of restless legs syndrome: Report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007, 8: 520-530.
7. Allen RP, Walters AS, Montplaisir J, et al.: Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165: 1286-1292.
8. Walters AS, LeBrocq C, Dhar A, et al.: Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003, 4: 121-132.
9. Garcia-BUrreguero D: Augmentation: understanding a key feature of RLS. Sleep Med 2004, 5: 5-6.
10. Collado-Seidel V, Kazenwadel J, Wetter TC, et al.: A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999, 52: 285-290.
11. Guilleminault C, Cetel M, Philip P: Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993, 43: 445.
12. Walters AS, Hening W, Rubinstein M, Chokroverty S: A clinical and polysomnographic comparison of neurolepticinduced akathisia and the idiopathic restless legs syndrome. Sleep 1991, 14: 339-345.
13. Inami Y, Horiguchi J, Nishimatsu O, et al.: A polysomnographic study on periodic limb movements in patients with restless legs syndrome and neuroleptic-induced akathisia. Hiroshima J Med Sci 1997, 46: 133-141.
14. Lipinski JF, Hudson JI, Cunningham SL, et al.: Polysomnographic characteristics of neuroleptic-induced akathisia. Clin Neuropharmacol 1991, 14: 413-419.
15. Trenkwalder C, Benes H, Grote L, et al.: Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. Mov Disord 2007, 22: 696-703.
16. Earley CJ, Allen RP: Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996, 19: 801-810.
17. Silber MH, Shepard JW Jr, Wisbey JA: Pergolide in the management of restless legs syndrome: An extended study. Sleep 1997, 20: 878-882.
18. Stiasny K, Wetter TC, Winkelmann J, et al.: Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001, 56: 1399-1402.
19. Ferini-Strambi L: Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002, 3(Suppl): S23-S25.
20. Winkelman JW, Johnston L: Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004, 5: 9-14.
21. Benes H, Heinrich CR, Ueberall MA, Kohnen R: Longterm safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: Results from an open-label 6-month clinical trial. Sleep 2004, 27: 674-682.
22. Stiasny-Kolster K, Benes H, Peglau I, et al.: Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004, 63: 2272-2279.
23. Högl B, Garcia-Borreguero D: Similar incidences of augmentation during 26 weeks of double-blind pramipexole treatment for restless legs syndrome in comparison to placebo [abstract]. Presented at the 61st Annual Meeting of the American Academy of Neurology. St Paul, MN: April 25-May 2, 2009.
24. Garcia-Borreguero D, Grunstein R, Sridhar G, et al.: A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007, 8: 742-752.
25. Benes H, Garcia-Borreguero D, Allen R, Kohnen R: Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine - a retrospective systematic analysis of two large open-label 1-year trials. Sleep 2009, 32: A307.
26. Earley CJ, Allen RP: Restless legs syndrome augmentation associated with tramadol. Sleep Med 2006, 7: 592-593.
27. Vetrugno R, La Morgia C, D'Angelo R, et al.: Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 2007, 22: 424-427.
28. Garcia-Borreguero D, Kohnen R, Högl B, et al.: Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007, 8: 455-463.
29. Garcia-Borreguero D, Allen RP, Benes H, et al.: Augmentation as a treatment complication of restless legs syndrome: Concept and management. Mov Disord 2007, 22(suppl): S476-S484.
30. Trenkwalder C, Hening WA, Montagna P, et al.: Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov Disord 2008, 23: 2267-2302.
31. Trenkwalder C, Högl B, Benes H, Kohnen R: Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008, 9: 572-574.
32. Allen R: Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004, 5: 385-391.
33. Davis BJ, Rajput A, Rajput ML, et al.: A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000, 43: 70-75.